Mar 15, 2026 by Seena HassounaA Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you?This clinical-stage biotech develops antibody therapies targeting autoimmune diseases, with a lead candidate in Phase II trials.
Mar 13, 2026 by Seena HassounaA Hedge Fund Just Trimmed $2.7 Million of NCR Voyix. Should You Care?NCR Voyix delivers technology and managed services across retail, hospitality, and financial services for enterprise clients worldwide.
